Wilson Therapeutics AB (PUBL) Interim Report January 1 – March 31, 2016
January 1 – March 31, 2016 · Net sales amounted to SEK 0.0 M (0.0). · Loss for the period was SEK 22.8 M (loss: 13.8) · Loss per share, before and after dilution, totaled SEK 17.52 (loss: 10.93) · At March 31, cash and cash equivalents amounted to SEK 53.0 M (8.9) Significant events during the period · A new share issue raised SEK 40.0 M, before issue costs of SEK 0.1 M Significant events after the end of the period · Resolution regarding a 1:10 share split · Data from the ongoing Phase II trial were presented at a major European Liver Conference · Wilson